Literature DB >> 29090086

The prospects of cariprazine in the treatment of schizophrenia.

Jonathan R Scarff1.   

Abstract

Entities:  

Year:  2017        PMID： 29090086      PMCID： PMC5638160          DOI： 10.1177/2045125317727260

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN： 2045-1253


× No keyword cloud information.
  10 in total

1.  Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.

Authors:  Jo C Neill; Ben Grayson; Béla Kiss; István Gyertyán; Paul Ferguson; Nika Adham
Journal:  Eur Neuropsychopharmacol       Date:  2015-11-19       Impact factor: 4.600

2.  Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study.

Authors:  Andrew J Cutler; Suresh Durgam; Yao Wang; Raffaele Migliore; Kaifeng Lu; István Laszlovszky; György Németh
Journal:  CNS Spectr       Date:  2017-05-08       Impact factor: 3.790

3.  Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.

Authors:  György Németh; István Laszlovszky; Pál Czobor; Erzsébet Szalai; Balázs Szatmári; Judit Harsányi; Ágota Barabássy; Marc Debelle; Suresh Durgam; István Bitter; Stephen Marder; W Wolfgang Fleischhacker
Journal:  Lancet       Date:  2017-02-07       Impact factor: 79.321

4.  The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia.

Authors:  David J G Watson; Madeleine V King; Istvan Gyertyán; Béla Kiss; Nika Adham; Kevin C F Fone
Journal:  Eur Neuropsychopharmacol       Date:  2015-12-11       Impact factor: 4.600

5.  Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine.

Authors:  Yong Kee Choi; Nika Adham; Béla Kiss; István Gyertyán; Frank I Tarazi
Journal:  CNS Spectr       Date:  2017-01-06       Impact factor: 3.790

6.  Mechanism of action of cariprazine.

Authors:  Stephen M Stahl
Journal:  CNS Spectr       Date:  2016-03-09       Impact factor: 3.790

7.  Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.

Authors:  Béla Kiss; Attila Horváth; Zsolt Némethy; Eva Schmidt; István Laszlovszky; Gyula Bugovics; Károly Fazekas; Katalin Hornok; Szabolcs Orosz; István Gyertyán; Eva Agai-Csongor; György Domány; Károly Tihanyi; Nika Adham; Zsolt Szombathelyi
Journal:  J Pharmacol Exp Ther       Date:  2010-01-21       Impact factor: 4.030

8.  The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials.

Authors:  Leslie Citrome; Suresh Durgam; Kaifeng Lu; Paul Ferguson; István Laszlovszky
Journal:  J Clin Psychiatry       Date:  2016-01       Impact factor: 4.384

9.  Cariprazine (RGH-188), a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats.

Authors:  V Román; I Gyertyán; K Sághy; B Kiss; Zs Szombathelyi
Journal:  Psychopharmacology (Berl)       Date:  2012-11-09       Impact factor: 4.530

Review 10.  New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine.

Authors:  Felix-Martin Werner; Rafael Coveñas
Journal:  Ther Clin Risk Manag       Date:  2015-11-02       Impact factor: 2.423
  10 in total
  3 in total

Review 1.  Current Concepts and Treatments of Schizophrenia.

Authors:  Piotr Stępnicki; Magda Kondej; Agnieszka A Kaczor
Journal:  Molecules       Date:  2018-08-20       Impact factor: 4.411

Review 2.  Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?

Authors:  Rajdip Barman; Pradipta Majumder; Tejaswini Doifode; Anita Kablinger
Journal:  World J Psychiatry       Date:  2021-12-19

3.  The novel atypical antipsychotic cariprazine demonstrates dopamine D2 receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity.

Authors:  Sarah Delcourte; Charles R Ashby; Renaud Rovera; Béla Kiss; Nika Adham; Bence Farkas; Nasser Haddjeri
Journal:  CNS Neurosci Ther       Date:  2018-05-04       Impact factor: 5.243
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.